View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Noble Life Sciences
21 January 2021

Live Animal Imaging in Oncology Preclinical Drug Development

Small animal optical imaging provides oncology researchers with the ability to perform non-invasive longitudinal monitoring of disease progression, detection of metastasis and micrometastasis, and to accurately quantify tumour burden in a wide variety of animal models. This can be used to effectively monitor and quantitate responses to therapeutics and develop translational biomarkers that can be used throughout your drug development program.

The sensitivity, versatility and non-invasive nature of combined luminescent and fluorescent imaging also provides additional capabilities such as longitudinal studies of cell trafficking, gene expression responses in living animals and a multitude of additional non-oncology uses including infectious disease, inflammation, cardiovascular disease, immunology, transplantation biology, and drug metabolism


Dr Stephen Horrigan, Chief Scientific Officer, Noble Life Sciences


Date:  February 10, 2021

Time: 1:00 pm ET

Registration Link: Please click here.

Diabetes is confirmed by both an absence of insulin and increase in blood glucose levels.
Skin serves as a barrier between the external environment and the underlying tissues. When the integrity of the skin is disrupted this barrier is compromised.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena